Supreme Court to hear challenge to Myriad gene patents, Bloomberg reports The U.S. Supreme Court agreed to consider a challenge to Myriad Genetics' (MYGN) and other biotechnology companies' right to be granted patents on human genes, reported Bloomberg. Reference Link
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
Myriad Genetics price target raised to $42 from $34 at Piper Jaffray Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.